Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock...
https://pubmed.ncbi.nlm.nih.gov/34170647/Actively Recruiting
Led by Tina Vilsbøll · Updated on 2025-05-22
124
Participants Needed
3
Research Sites
71 weeks
Total Duration
Researchers are evaluating the long-term effects of tirzepatide, given once weekly, compared to placebo on coronary plaque composition, plaque burden, and microvascular function in overweight and obese adults with stable coronary artery disease CAD. This Phase 4 proof-of-principle study aims to explore how tirzepatide may reduce coronary lipid accumulation and the progression of atheromatosis in individuals with high-risk atherosclerosis. The study also includes a baseline sub-study to identify metabolic and cardiovascular predictors of high arteriosclerotic plaque burden and to build a cohort for future research. Participants will be randomly assigned to receive either tirzepatide or placebo as a once-weekly subcutaneous injection for 52 weeks. Tirzepatide is an investigational drug studied for its anti-atherogenic effects, while placebo injections match in volume and excipients but contain no active drug. The study uses advanced imaging techniques including near-infrared spectroscopy NIRS and intravascular ultrasound IVUS to assess changes in plaque lipid content and burden. Microvascular function will be evaluated using coronary flow reserve measurements. Throughout the 52-week treatment period, participants will undergo detailed assessments including imaging to measure lipid core burden index and percent atheroma volume. Researchers will monitor coronary flow reserve and the number of high-risk coronary lesions to evaluate treatment effects. Safety monitoring and follow-up will continue throughout the study duration, with data collected to understand tirzepatides impact on coronary plaque and microvascular function in this population.
CONDITIONS
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
D
Daniel Raaschou-Oddershede, MD
C
Christine Rode Schwarz, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tina Vilsbøll
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 52 weeks
Participants receive once-weekly subcutaneous injections of tirzepatide or placebo for 52 weeks to study effects on coronary plaque and atheromatosis.
Weekly visits for injections
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Juan P Frías, Melanie J Davies, Julio Rosenstock...
https://pubmed.ncbi.nlm.nih.gov/34170647/Smita I Negi, Romain Didier, Hideki Ota...
https://pubmed.ncbi.nlm.nih.gov/26242984/Satoshi Honda, Samuel L Sidharta, Daisuke Shishikura...
https://pubmed.ncbi.nlm.nih.gov/28881268/Kazuto Nakamura, José J Fuster, Kenneth Walsh
https://pubmed.ncbi.nlm.nih.gov/24355497/Shu Chen, Fumiaki Okahara, Noriko Osaki...
https://pubmed.ncbi.nlm.nih.gov/25537494/Flavio Giuseppe Biccirè, Simone Budassi, Yukio Ozaki...
https://pubmed.ncbi.nlm.nih.gov/35718858/Irene Caruso, Angelo Cignarelli, Francesco Giorgino
https://pubmed.ncbi.nlm.nih.gov/31401015/Alan D Lopez, Tim Adair
https://pubmed.ncbi.nlm.nih.gov/31378814/NCD Risk Factor Collaboration (NCD-RisC)
https://pubmed.ncbi.nlm.nih.gov/27115820/Juan Pablo Frias, Michael A Nauck, Joanna Van...
https://pubmed.ncbi.nlm.nih.gov/30293770/Tina Vilsbøll
Lead Sponsor